ClinicalTrials.gg
CompletedNCT00925600Updated May 30, 2017Results posted

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

A Phase 3 interventional study of Denosumab and Placebo in Cancer, Cataract and Low Bone Mineral Density, sponsored by Amgen. Completed at 172 sites in 18 countries. Open to male participants aged 30 Years to 120 Years. Per ClinicalTrials.gov, last updated 2017-05-30.

Primary conditionProstatic NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Prostatic Neoplasms
Why
  1. The study's listed conditions name Prostatic Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
769
Allocation
Randomized
Ages
30 Years to 120 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing denosumab in Prostatic Neoplasms — none open to participants now, none under way, none of them phase 3. Denosumab · Prostatic Neoplasms.

Enrollment
4th of 10
769 · median 324
Started
2009
with 2 others
Phase 3
8 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
7 of 10
Amgen

Among the 10 studies testing denosumab in Prostatic Neoplasms, this one is the 4th largest by enrollment, is one of 3 that started in 2009, is one of 8 in phase 3, and was the 4th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

None of the 10 studies testing denosumab in Prostatic Neoplasms is open now. The open studies under Prostatic Neoplasms, anywhere →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 30 Years to 120 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing denosumab in Prostatic Neoplasms as a file.
02

Study summary

This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate new or worsening lens opacifications in men with non-metastatic prostate cancer receiving denosumab for bone loss due to androgen deprivation therapy.

03

Conditions studied

  • Cancer
  • Cataract
  • Low Bone Mineral Density
  • Osteopenia
  • Osteoporosis
  • Prostate Cancer

Keywords

  • Lens Opacification
  • Bone Loss
  • Androgen Deprivation Therapy
  • Non-metastatic prostate cancer
04

In context

Prostatic Neoplasms Reclassified

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

This study's enrollment of 769 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Prostatic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
30 Years to 120 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men ≥ 30 years of age with non- prostate cancer, having undergone bilateral orchiectomy or initiated androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists and is expected to continue on ADT for at least 12 months
  • Adequate visual accuracy allowing eye testing
  • Bone Mineral Density (BMD) requirements: Osteopenia if under 70 years of age; Osteopenia or normal BMD if over 70 years of age
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Previous surgery for cataracts in both eyes, current diagnosis of cataracts, cataracts surgery foreseen in the near future, or ocular disease leading to visual loss
  • Diagnosis of osteoporosis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
769 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo administered by subcutaneous injection on Day 1 and at Month 6.

    Biological: Placebo

  • Experimental
    Denosumab

    Participants received denosumab 60 mg administered by subcutaneous injection on Day 1 and at Month 6.

    Biological: Denosumab

Interventions

  • BiologicalDenosumab

    Prefilled syringe for subcutaneous (SC) injection administered at a dose of 60 mg

    Also known as: Prolia®

  • BiologicalPlacebo

    Prefilled syringe for subcutaneous (SC) injection

07

What researchers measure

Primary outcomes

  1. Percentage of Participants With Lens Opacification Event Development or Progression by Month 12

    The Lens Opacities Classification System III (LOCS III) is a slit lamp based opacification grading method. Photographs of slit lamp cross-sections of the lens are used as references for grading nuclear opalescence (NO) and nuclear color (NC), and photographs of the lens seen by retroillumination are used as references for grading cortical (C) and posterior subcapsular (P) cataract. Opacification severity is graded on a decimal scale, scores can range from 0.1 to 6.9 for NO and NC and from 0.1 to 5.9 for C and P. For each opacification type the higher grading scores indicate greater severity. Lens opacification event development or progression by month 12 was based on a change of ≥ 1.0 in P, ≥ 1.0 in C, or ≥ 0.7 in NO in the LOCS III score from baseline.

    Time frame: 12 months

Other outcomes

  1. Percentage of Participant With Lens Opacification Event Development or Progression by Month 12 Based on a Change of ≥ 1.5 in P, ≥ 1.5 in C, or ≥ 1.5 in NO in the LOCS III Score

    The Lens Opacities Classification System III (LOCS III) is a slit lamp based opacification grading method. Photographs of slit lamp cross-sections of the lens are used as references for grading nuclear opalescence (NO) and nuclear color (NC), and photographs of the lens seen by retroillumination are used as references for grading cortical (C) and posterior subcapsular (P) cataract. Opacification severity is graded on a decimal scale, scores can range from 0.1 to 6.9 for NO and NC and from 0.1 to 5.9 for C and P. For each opacification type the higher grading scores indicate greater severity. Lens opacification event development or progression by month 12 was based on a change ≥ 1.5 in P, ≥ 1.5 in C, or ≥ 1.5 in NO in the LOCS III score from baseline.

    Time frame: 12 months

  2. Percentage of Participants With Lens Opacification Event Development or Progression by Month 6

    The Lens Opacities Classification System III (LOCS III) is a slit lamp based opacification grading method. Photographs of slit lamp cross-sections of the lens are used as references for grading nuclear opalescence (NO) and nuclear color (NC), and photographs of the lens seen by retroillumination are used as references for grading cortical (C) and posterior subcapsular (P) cataract. Opacification severity is graded on a decimal scale, scores can range from 0.1 to 6.9 for NO and NC and from 0.1 to 5.9 for C and P. For each opacification type the higher grading scores indicate greater severity. Lens opacification event development or progression by month 6 was based on a change of ≥ 1.0 in P, ≥ 1.0 in C, or ≥ 0.7 in NO in the LOCS III score from baseline.

    Time frame: 6 months

  3. Percentage of Participants With Confirmed Lens Opacification Event Development or Progression by Month 12

    The Lens Opacities Classification System III (LOCS III) is a slit lamp based opacification grading method. Photographs of slit lamp cross-sections of the lens are used as references for grading nuclear opalescence (NO) and nuclear color (NC), and photographs of the lens seen by retroillumination are used as references for grading cortical (C) and posterior subcapsular (P) cataract. Opacification severity is graded on a decimal scale, scores can range from 0.1 to 6.9 for NO and NC and from 0.1 to 5.9 for C and P. For each opacification type the higher grading scores indicate greater severity. Lens opacification event development or progression by month 12 was based on a change of ≥ 1.0 in P, ≥ 1.0 in C, or ≥ 0.7 in NO in the LOCS III score from baseline. A confirmed lens opacification event development or progression was defined as 2 directly subsequent events per protocol assessments at the same location (P, C, NO) using LOCS III as above.

    Time frame: 12 months

  4. Percentage of Participants With a Decrease From Baseline in Best Corrected Visual Acuity (BCVA) of ≥ 10 Letters

    The best corrected visual acuity (BCVA) is the best vision one can achieve with correction (such as eye glasses) as measured on an eye chart. BCVA was assessed by a trained ophthalmologist using the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart at 4 meters. The modified University of Crete ETDRS chart was used in Ukraine, Greece, Russia and Bulgaria, which do not use the Roman alphabet. The 2000 series revised ETDRS chart was used to assess the change in all other countries. The letter score was calculated based on the number of letters that were correctly identified; higher letter scores correspond to better visual acuity.

    Time frame: Baseline and Months 3, 6, 9 and 12

  5. Change From Baseline in Refraction Needed to Achieve BCVA

    Refraction error was measured using a phoropter. The change from baseline in spherical refraction error needed to achieve BCVA is reported.

    Time frame: Baseline and months 3, 6, 9, and 12

  6. Number of Participants With Adverse Events

    Adverse events (AEs) were assessed for severity by the investigator according to the Common Terminology Criteria for Adverse Events (CTCAE) severity grading scale, version 3.0, where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe AE, Grade 4 =Life-threatening AE and Grade 5 = Death due to AE. Treatment-related AEs (TRAEs) include only events for which the investigator indicated there was a reasonable possibility they may have been caused by the study drug.

    Time frame: 12 months

08

Results

Posted May 30, 2017

Participant flow

This study was conducted at 125 centers in 18 countries: Australia, Bulgaria, Canada, the Czech Republic, France, Greece, Hungary, India, Latvia, Mexico, New Zealand, Poland, Russia, Slovakia, Slovenia, South Africa, Ukraine, and the United States. The first participant enrolled on 30 November 2009 and the last participant enrolled on 04 May 2015.

Participant flow — Overall Study
MilestonePlaceboDenosumab
Started386383
Received treatment383382
Completed354355
Not completed3228
Withdrew: Withdrawal by subject1614
Withdrew: Death43
Withdrew: Lost to follow-up22
Withdrew: Disease progression13
Withdrew: Administrative decision11
Withdrew: Noncompliance20
Withdrew: Ineligibility determined20
Withdrew: Protocol deviation01
Withdrew: Requirement for alternative therapy01
Withdrew: Other31
Withdrew: Adverse event12

Outcome measures

PrimaryPercentage of Participants With Lens Opacification Event Development or Progression by Month 12

The Lens Opacities Classification System III (LOCS III) is a slit lamp based opacification grading method. Photographs of slit lamp cross-sections of the lens are used as references for grading nuclear opalescence (NO) and nuclear color (NC), and photographs of the lens seen by retroillumination are used as references for grading cortical (C) and posterior subcapsular (P) cataract. Opacification severity is graded on a decimal scale, scores can range from 0.1 to 6.9 for NO and NC and from 0.1 to 5.9 for C and P. For each opacification type the higher grading scores indicate greater severity. Lens opacification event development or progression by month 12 was based on a change of ≥ 1.0 in P, ≥ 1.0 in C, or ≥ 0.7 in NO in the LOCS III score from baseline.

Time frame:
12 months
Reported as:
Number · percentage of participants
Percentage of Participants With Lens Opacification Event Development or Progression by Month 12
percentage of participantsPlaceboDenosumab
Percentage of Participants With Lens Opacification Event Development or Progression by Month 1233.233.5
Statistical analysis
  • Placebo vs Denosumab · Mantel Haenszel · p = 0.0026 · Risk difference (rd): 0.4 · 95% CI -6.3 to 7.2
Other pre-specifiedPercentage of Participant With Lens Opacification Event Development or Progression by Month 12 Based on a Change of ≥ 1.5 in P, ≥ 1.5 in C, or ≥ 1.5 in NO in the LOCS III Score

The Lens Opacities Classification System III (LOCS III) is a slit lamp based opacification grading method. Photographs of slit lamp cross-sections of the lens are used as references for grading nuclear opalescence (NO) and nuclear color (NC), and photographs of the lens seen by retroillumination are used as references for grading cortical (C) and posterior subcapsular (P) cataract. Opacification severity is graded on a decimal scale, scores can range from 0.1 to 6.9 for NO and NC and from 0.1 to 5.9 for C and P. For each opacification type the higher grading scores indicate greater severity. Lens opacification event development or progression by month 12 was based on a change ≥ 1.5 in P, ≥ 1.5 in C, or ≥ 1.5 in NO in the LOCS III score from baseline.

Time frame:
12 months
Reported as:
Number · percentage of participants
Percentage of Participant With Lens Opacification Event Development or Progression by Month 12 Based on a Change of ≥ 1.5 in P, ≥ 1.5 in C, or ≥ 1.5 in NO in the LOCS III Score
percentage of participantsPlaceboDenosumab
Percentage of Participant With Lens Opacification Event Development or Progression by Month 12 Based on a Change of ≥ 1.5 in P, ≥ 1.5 in C, or ≥ 1.5 in NO in the LOCS III Score10.78.4
Statistical analysis
  • Placebo vs Denosumab · Risk difference (rd): -2.2 · 95% CI -6.4 to 2.0
Other pre-specifiedPercentage of Participants With Lens Opacification Event Development or Progression by Month 6

The Lens Opacities Classification System III (LOCS III) is a slit lamp based opacification grading method. Photographs of slit lamp cross-sections of the lens are used as references for grading nuclear opalescence (NO) and nuclear color (NC), and photographs of the lens seen by retroillumination are used as references for grading cortical (C) and posterior subcapsular (P) cataract. Opacification severity is graded on a decimal scale, scores can range from 0.1 to 6.9 for NO and NC and from 0.1 to 5.9 for C and P. For each opacification type the higher grading scores indicate greater severity. Lens opacification event development or progression by month 6 was based on a change of ≥ 1.0 in P, ≥ 1.0 in C, or ≥ 0.7 in NO in the LOCS III score from baseline.

Time frame:
6 months
Reported as:
Number · percentage of participants
Percentage of Participants With Lens Opacification Event Development or Progression by Month 6
percentage of participantsPlaceboDenosumab
Percentage of Participants With Lens Opacification Event Development or Progression by Month 619.319.0
Statistical analysis
  • Placebo vs Denosumab · Risk difference (rd): -0.3 · 95% CI -5.9 to 5.3
Other pre-specifiedPercentage of Participants With Confirmed Lens Opacification Event Development or Progression by Month 12

The Lens Opacities Classification System III (LOCS III) is a slit lamp based opacification grading method. Photographs of slit lamp cross-sections of the lens are used as references for grading nuclear opalescence (NO) and nuclear color (NC), and photographs of the lens seen by retroillumination are used as references for grading cortical (C) and posterior subcapsular (P) cataract. Opacification severity is graded on a decimal scale, scores can range from 0.1 to 6.9 for NO and NC and from 0.1 to 5.9 for C and P. For each opacification type the higher grading scores indicate greater severity. Lens opacification event development or progression by month 12 was based on a change of ≥ 1.0 in P, ≥ 1.0 in C, or ≥ 0.7 in NO in the LOCS III score from baseline. A confirmed lens opacification event development or progression was defined as 2 directly subsequent events per protocol assessments at the same location (P, C, NO) using LOCS III as above.

Time frame:
12 months
Reported as:
Number · percentage of participants
Percentage of Participants With Confirmed Lens Opacification Event Development or Progression by Month 12
percentage of participantsPlaceboDenosumab
Percentage of Participants With Confirmed Lens Opacification Event Development or Progression by Month 1218.316.1
Statistical analysis
  • Placebo vs Denosumab · Risk difference (rd): -2.2 · 95% CI -7.6 to 3.3
Other pre-specifiedPercentage of Participants With a Decrease From Baseline in Best Corrected Visual Acuity (BCVA) of ≥ 10 Letters

The best corrected visual acuity (BCVA) is the best vision one can achieve with correction (such as eye glasses) as measured on an eye chart. BCVA was assessed by a trained ophthalmologist using the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart at 4 meters. The modified University of Crete ETDRS chart was used in Ukraine, Greece, Russia and Bulgaria, which do not use the Roman alphabet. The 2000 series revised ETDRS chart was used to assess the change in all other countries. The letter score was calculated based on the number of letters that were correctly identified; higher letter scores correspond to better visual acuity.

Time frame:
Baseline and Months 3, 6, 9 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease From Baseline in Best Corrected Visual Acuity (BCVA) of ≥ 10 Letters
percentage of participantsPlaceboDenosumab
Month 3 (n = 372, 375)5.46.1
Month 6 (n = 355, 357)4.26.4
Month 9 (n = 350, 346)4.66.6
Month 12 (n = 343, 342)5.27.3
Other pre-specifiedChange From Baseline in Refraction Needed to Achieve BCVA

Refraction error was measured using a phoropter. The change from baseline in spherical refraction error needed to achieve BCVA is reported.

Time frame:
Baseline and months 3, 6, 9, and 12
Reported as:
Mean · diopters
Change From Baseline in Refraction Needed to Achieve BCVA
dioptersPlacebo - Left EyePlacebo - Right EyeDenosumabDenosumab - Right Eye
Month 3 (n = 362, 358, 358, 359)0.01 ± 0.600.01 ± 0.490.05 ± 0.730.04 ± 0.51
Month 6 (n = 347, 343, 341, 344)-0.01 ± 0.800.06 ± 0.700.06 ± 0.900.04 ± 0.59
Month 9 (n = 341, 339, 332, 332)0.00 ± 0.840.01 ± 0.730.04 ± 0.750.01 ± 0.62
Month 12 (n = 336, 334, 328, 329)-0.03 ± 0.70-0.04 ± 0.590.03 ± 0.770.00 ± 0.48
Other pre-specifiedNumber of Participants With Adverse Events

Adverse events (AEs) were assessed for severity by the investigator according to the Common Terminology Criteria for Adverse Events (CTCAE) severity grading scale, version 3.0, where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe AE, Grade 4 =Life-threatening AE and Grade 5 = Death due to AE. Treatment-related AEs (TRAEs) include only events for which the investigator indicated there was a reasonable possibility they may have been caused by the study drug.

Time frame:
12 months
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsPlaceboDenosumab
Any adverse event193191
Serious adverse events5242
AE leading to discontinuation of study drug57
AE leading to discontinuation from study24
Fatal adverse events43
AE grade 3, 4, or 55346
Treatment-related adverse events1921
Serious treatment-related adverse events12
TRAE leading to discontinuation of study drug13
TRAE leading to discontinuation from study01
Fatal treatment-related adverse events00
TRAE grade 3, 4, or 522

Adverse events

Collected over 12 months. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—52/380 (13.7%)107/380 (28.2%)
Denosumab—42/385 (10.9%)121/385 (31.4%)
Most frequent serious events
Showing 10 of 97
Most frequent serious events
EventPlaceboDenosumab
Cerebrovascular accidentNervous system disorders4/3801/385
Myocardial ischaemiaCardiac disorders1/3803/385
Coronary artery diseaseCardiac disorders2/3801/385
Myocardial infarctionCardiac disorders2/3801/385
DiarrhoeaGastrointestinal disorders2/3800/385
DiverticulitisInfections and infestations2/3800/385
PneumoniaInfections and infestations2/3800/385
DizzinessNervous system disorders2/3800/385
Acute kidney injuryRenal and urinary disorders2/3800/385
Urinary retentionRenal and urinary disorders2/3800/385
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPlaceboDenosumab
ConstipationGastrointestinal disorders16/3808/385
HypertensionVascular disorders16/3808/385
ArthralgiaMusculoskeletal and connective tissue disorders10/38012/385
Back painMusculoskeletal and connective tissue disorders10/38011/385
Pain in extremityMusculoskeletal and connective tissue disorders10/3806/385
NasopharyngitisInfections and infestations7/38010/385
Hot flushVascular disorders7/3807/385
Oedema peripheralGeneral disorders1/3807/385
OsteoarthritisMusculoskeletal and connective tissue disorders2/3807/385
PollakiuriaRenal and urinary disorders6/3807/385

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboDenosumabTotal
Mean71.0 ± 7.071.1 ± 7.271.0 ± 7.1
Age, Customized
Age, Customized(participants)PlaceboDenosumabTotal
18 - 64 years7366139
65 - 74 years189194383
75 - 84 years119116235
≥ 85 years5712
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDenosumabTotal
Female000
Male386383769
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboDenosumabTotal
White359346705
Black (or African American)121123
Hispanic/Latino1910
Other7815
Asian7714
Japanese011
Native Hawaiian or Other Pacific Islander011
Presence of Cataract(s)
Presence of Cataract(s)(participants)PlaceboDenosumabTotal
Yes5963122
No327320647
Presence of Diabetes
Presence of Diabetes(participants)PlaceboDenosumabTotal
Yes7061131
No316322638
Received Androgen-deprivation Therapy (ADT)
Received Androgen-deprivation Therapy (ADT)(participants)PlaceboDenosumabTotal
Yes350353703
No363066
Orchiectomy (Surgical Castration)
Orchiectomy (Surgical Castration)(participants)PlaceboDenosumabTotal
Yes5851109
No328332660

2 further baseline measures are reported on the registry.

09

Study locations

172 sites
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Laguna Hills, California 92653, United States
  • Research Site
    Murrieta, California 92562, United States
  • Research Site
    San Diego, California 92103, United States
  • Research Site
    San Diego, California 92120, United States
  • Research Site
    San Diego, California 92123, United States
  • Research Site
    San Luis Obispo, California 93405, United States
  • Research Site
    Denver, Colorado 80204, United States
  • Research Site
    Denver, Colorado 80211, United States
  • Research Site
    Englewood, Colorado 80113, United States
  • Research Site
    Middlebury, Connecticut 06762, United States
  • Research Site
    New Britain, Connecticut 06052, United States
  • Research Site
    Trinity, Florida 34655, United States
  • Research Site
    Coeur d'Alene, Idaho 83814, United States
  • Research Site
    Greenwood, Indiana 46143, United States
  • Research Site
    West Des Moines, Iowa 50266, United States
  • Research Site
    Kansas City, Kansas 66160, United States
  • Research Site
    Shreveport, Louisiana 71106, United States
  • Research Site
    Annapolis, Maryland 21401, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Greenbelt, Maryland 20770, United States
  • Research Site
    Grand Rapids, Michigan 49546, United States
  • Research Site
    Sartell, Minnesota 56377, United States
  • Research Site
    Saint Louis, Missouri 63110, United States
  • Research Site
    Missoula, Montana 59808, United States
  • Research Site
    Omaha, Nebraska 68105-1850, United States
  • Research Site
    Omaha, Nebraska 68130, United States
  • Research Site
    Berlin, New Jersey 08009, United States
  • Research Site
    Bricktown, New Jersey 08724, United States
  • Research Site
    Englewood, New Jersey 07631, United States
  • Research Site
    Lawrenceville, New Jersey 08648, United States
  • Research Site
    Mount Laurel, New Jersey 08054, United States
  • Research Site
    Albany, New York 12208, United States
  • Research Site
    Garden City, New York 11530, United States
  • Research Site
    Kingston, New York 12401, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    Poughkeepsie, New York 12601, United States
  • Research Site
    Syracuse, New York 13210, United States
  • Research Site
    Gastonia, North Carolina 28054, United States
  • Research Site
    Greenville, North Carolina 27834, United States
  • Research Site
    Cincinnati, Ohio 45212, United States
  • Research Site
    Bala-Cynwyd, Pennsylvania 19004, United States
  • Research Site
    Lancaster, Pennsylvania 17604, United States
  • Research Site
    Philadelphia, Pennsylvania 19107, United States
  • Research Site
    Myrtle Beach, South Carolina 29572, United States
  • Research Site
    Knoxville, Tennessee 37920, United States
  • Research Site
    Austin, Texas 78759, United States
  • Research Site
    Dallas, Texas 75231, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Temple, Texas 76508, United States
  • Research Site
    Richmond, Virginia 23235, United States
  • Research Site
    Salem, Virginia 24153, United States
  • Research Site
    Wahroonga, New South Wales 2076, Australia
  • Research Site
    Herston, Queensland 4029, Australia
  • Research Site
    Bentleigh East, Victoria 3165, Australia
  • Research Site
    Ringwood East, Victoria 3135, Australia
  • Research Site
    Pleven, 5800, Bulgaria
  • Research Site
    Plovdiv, 4004, Bulgaria
  • Research Site
    Sofia, 1784, Bulgaria
  • Research Site
    Kelowna, British Columbia V1W 4V5, Canada
  • Research Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Research Site
    Victoria, British Columbia V8T 5G1, Canada
  • Research Site
    Victoria, British Columbia V8V 3N1, Canada
  • Research Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Research Site
    Barrie, Ontario L4M 7G1, Canada
  • Research Site
    Brampton, Ontario L6T 4S5, Canada
  • Research Site
    Brantford, Ontario N3S 6T6, Canada
  • Research Site
    Burlington, Ontario L7N 3V2, Canada
  • Research Site
    Guelph, Ontario N1H 5J1, Canada
  • Research Site
    Kitchener, Ontario N2N 2B9, Canada
  • Research Site
    London, Ontario N6A 4G5, Canada
  • Research Site
    Newmarket, Ontario L3X 1W1, Canada
  • Research Site
    North Bay, Ontario P1B 7K8, Canada
  • Research Site
    North York, Ontario M3B 3S6, Canada
  • Research Site
    Oakville, Ontario L6H 3P1, Canada
  • Research Site
    Scarborough, Ontario M1P 2T7, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Toronto, Ontario M6A 3B5, Canada
  • Research Site
    Laval, Quebec H7G 2E6, Canada
  • Research Site
    Montreal, Quebec H2L 4M1, Canada
  • Research Site
    Benesov, 256 01, Czechia
  • Research Site
    Brno, 612 00, Czechia
  • Research Site
    Hradec Kralove, 500 05, Czechia
  • Research Site
    Jindrichuv Hradec, 377 01, Czechia
  • Research Site
    Kromeriz, 767 55, Czechia
  • Research Site
    Novy Jicin, 741 01, Czechia
  • Research Site
    Olomouc, 775 20, Czechia
  • Research Site
    Plzen, 305 99, Czechia
  • Research Site
    Praha 2, 120 00, Czechia
  • Research Site
    Praha 4, 140 00, Czechia
  • Research Site
    Praha 6, 160 00, Czechia
  • Research Site
    Usti nad Labem, 401 13, Czechia
  • Research Site
    Zlin, 760 01, Czechia
  • Research Site
    Lyon Cédex 3, 69437, France
  • Research Site
    Paris Cedex 5, 75248, France
  • Research Site
    Alexandroupoli, 68100, Greece
  • Research Site
    Athens, 11522, Greece
  • Research Site
    Athens, 11526, Greece
  • Research Site
    Athens, 11527, Greece

Showing the first 100 of 172 sites across 18 countries. Choose a country and city above to see the rest.

10

References and documents

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2009 to primary completion in May 2016, 77 months.

Results were first posted in May 2017, 1 year after primary completion.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 77 months is above that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2009
First posted
Jun 22, 2009
StartActual
Nov 30, 2009
Primary completionActual
May 12, 2016
CompletionActual
May 12, 2016
Results first posted
May 30, 2017
Last update
May 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00925600
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jun 22, 2009
Start date
Nov 30, 2009
Primary completion
May 12, 2016
Completion
May 12, 2016
Results posted
May 30, 2017
Last update
May 30, 2017

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion